<DOC>
	<DOCNO>NCT01475305</DOCNO>
	<brief_summary>The primary goal evaluate suitability Respiratory Syncytial Virus ( RSV ) challenge model measure efficacy MEDI-557 compare placebo healthy adult subject reduction incidence RSV 12 day post-RSV challenge RSV virus .</brief_summary>
	<brief_title>Intra-nasal Challenge Healthy Adults With Respiratory Syncytial Virus ( RSV )</brief_title>
	<detailed_description>This design double-blind , placebo-controlled , randomize study . Up 30 subject randomize , dose follow . Subjects randomly assign receive single intravenous ( IV ) dose MEDI-557 placebo . Subjects inoculate RSV . Subjects follow efficacy 12 day post-RSV challenge . Safety follow-up approximately 12 month randomization .</detailed_description>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Healthy determine medical history physical examination . 2 . Age 18 45 year time screen . 3 . Written inform consent locally require authorization obtain subject prior performing protocolrelated procedure , include screen evaluation . 4 . Weight â‰¤110 kg body mass index ( BMI ) &lt; 32 kg/m2 . 5 . Normotensive ( systolic blood pressure [ BP ] &lt; 150 mmHg diastolic BP &lt; 90 mmHg ) . 6 . Females childbearing age use contraception . 7 . Males sexually active female partner childbearing potential , use contraception . Current medical condition follow : 1 . Clinical evidence chronic pulmonary disease use bronchodilator asthma medication . 2 . Current smoker unwilling/unable desist quarantine phase study 3 . History clinical evidence recurrent low respiratory tract infection 4 . Evidence infection hepatitis A , B , C virus human immunodeficiency virus ( HIV ) serology . Medical history follow : 5 ) History immunodeficiency . 6 ) History chronic sinusitis . 7 ) Prior/concomitant therapy include Receipt systemic chemotherapeutic agent time ; Receipt systemic glucocorticoid within 1 month , immunosuppressive drug within 6 month prior challenge . Receipt investigational drug within 6 month prior dose concurrent enrolment another clinical study . Prior participation clinical trial experimental RSV viral challenge deliver directly respiratory tract time , respiratory virus challenge within 1 year prior dose . 8 ) Nursing mother . 9 ) Alcohol drug addiction/abuse within past 2 year . 10 ) A positive urine Class A drug alcohol screen unless medical reason 11 ) History seasonal hay fever seasonal allergy 12 ) Employees clinical study site sponsor , individual involve conduct study , immediate family member individual . 13 ) Health care worker anticipate patient contact within 2 week viral challenge . 14 ) Subjects , additional 2 week discharge isolation facility , likely contact household member close contact someone : ( ) less 3 year age ; ( b ) person know immunodeficiency ; ( c ) person receive immunosuppressant medication ; ( ) person undergo soon undergo cancer chemotherapy within 28 day challenge ; ( e ) person diagnose emphysema COPD , elderly reside nursing home , severe lung disease medical condition ; ( f ) person receive transplant ( bone marrow solid organ ) . 15 ) As result medical interview , physical examination , screen investigation , investigator ( ) considers subject unfit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>RSV , Healthy adult , MEDI-557 , intranasal challenge , human model</keyword>
</DOC>